Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 57

1.

Targeting Hsp90 in urothelial carcinoma.

Chehab M, Caza T, Skotnicki K, Landas S, Bratslavsky G, Mollapour M, Bourboulia D.

Oncotarget. 2015 Mar 26. [Epub ahead of print]

2.

Asymmetric Hsp90 N domain SUMOylation recruits Aha1 and ATP-competitive inhibitors.

Mollapour M, Bourboulia D, Beebe K, Woodford MR, Polier S, Hoang A, Chelluri R, Li Y, Guo A, Lee MJ, Fotooh-Abadi E, Khan S, Prince T, Miyajima N, Yoshida S, Tsutsumi S, Xu W, Panaretou B, Stetler-Stevenson WG, Bratslavsky G, Trepel JB, Prodromou C, Neckers L.

Mol Cell. 2014 Jan 23;53(2):317-29. doi: 10.1016/j.molcel.2013.12.007.

3.

The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and -resistant MET-driven tumor models.

Miyajima N, Tsutsumi S, Sourbier C, Beebe K, Mollapour M, Rivas C, Yoshida S, Trepel JB, Huang Y, Tatokoro M, Shinohara N, Nonomura K, Neckers L.

Cancer Res. 2013 Dec 1;73(23):7022-33. doi: 10.1158/0008-5472.CAN-13-1156. Epub 2013 Oct 11.

4.

Posttranslational modification and conformational state of heat shock protein 90 differentially affect binding of chemically diverse small molecule inhibitors.

Beebe K, Mollapour M, Scroggins B, Prodromou C, Xu W, Tokita M, Taldone T, Pullen L, Zierer BK, Lee MJ, Trepel J, Buchner J, Bolon D, Chiosis G, Neckers L.

Oncotarget. 2013 Jul;4(7):1065-74.

5.

Contributions of co-chaperones and post-translational modifications towards Hsp90 drug sensitivity.

Walton-Diaz A, Khan S, Bourboulia D, Trepel JB, Neckers L, Mollapour M.

Future Med Chem. 2013 Jun;5(9):1059-71. doi: 10.4155/fmc.13.88. Review.

PMID:
23734688
6.

Combined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis in cancer cells.

Iwai A, Bourboulia D, Mollapour M, Jensen-Taubman S, Lee S, Donnelly AC, Yoshida S, Miyajima N, Tsutsumi S, Smith AK, Sun D, Wu X, Blagg BS, Trepel JB, Stetler-Stevenson WG, Neckers L.

Cell Cycle. 2012 Oct 1;11(19):3649-55. doi: 10.4161/cc.21926. Epub 2012 Aug 30.

7.

Tumor-intrinsic and tumor-extrinsic factors impacting hsp90- targeted therapy.

Alarcon SV, Mollapour M, Lee MJ, Tsutsumi S, Lee S, Kim YS, Prince T, Apolo AB, Giaccone G, Xu W, Neckers LM, Trepel JB.

Curr Mol Med. 2012 Nov 1;12(9):1125-41. Review.

8.

Dynamic tyrosine phosphorylation modulates cycling of the HSP90-P50(CDC37)-AHA1 chaperone machine.

Xu W, Mollapour M, Prodromou C, Wang S, Scroggins BT, Palchick Z, Beebe K, Siderius M, Lee MJ, Couvillon A, Trepel JB, Miyata Y, Matts R, Neckers L.

Mol Cell. 2012 Aug 10;47(3):434-43. doi: 10.1016/j.molcel.2012.05.015. Epub 2012 Jun 21.

9.

Charged linker sequence modulates eukaryotic heat shock protein 90 (Hsp90) chaperone activity.

Tsutsumi S, Mollapour M, Prodromou C, Lee CT, Panaretou B, Yoshida S, Mayer MP, Neckers LM.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2937-42. doi: 10.1073/pnas.1114414109. Epub 2012 Feb 6.

10.
11.

Detecting HSP90 phosphorylation.

Mollapour M, Neckers L.

Methods Mol Biol. 2011;787:67-74. doi: 10.1007/978-1-61779-295-3_5.

PMID:
21898227
12.

Post-translational modifications of Hsp90 and their contributions to chaperone regulation.

Mollapour M, Neckers L.

Biochim Biophys Acta. 2012 Mar;1823(3):648-55. doi: 10.1016/j.bbamcr.2011.07.018. Epub 2011 Aug 10. Review.

13.

Casein kinase 2 phosphorylation of Hsp90 threonine 22 modulates chaperone function and drug sensitivity.

Mollapour M, Tsutsumi S, Kim YS, Trepel J, Neckers L.

Oncotarget. 2011 May;2(5):407-17.

14.

Threonine 22 phosphorylation attenuates Hsp90 interaction with cochaperones and affects its chaperone activity.

Mollapour M, Tsutsumi S, Truman AW, Xu W, Vaughan CK, Beebe K, Konstantinova A, Vourganti S, Panaretou B, Piper PW, Trepel JB, Prodromou C, Pearl LH, Neckers L.

Mol Cell. 2011 Mar 18;41(6):672-81. doi: 10.1016/j.molcel.2011.02.011.

15.

Regulatory posttranslational modifications in hsp90 can be compensated by cochaperone aha1.

Schmid S, Hugel T.

Mol Cell. 2011 Mar 18;41(6):619-20. doi: 10.1016/j.molcel.2011.02.028.

16.

A systematic protocol for the characterization of Hsp90 modulators.

Matts RL, Brandt GE, Lu Y, Dixit A, Mollapour M, Wang S, Donnelly AC, Neckers L, Verkhivker G, Blagg BS.

Bioorg Med Chem. 2011 Jan 1;19(1):684-92. doi: 10.1016/j.bmc.2010.10.029. Epub 2010 Oct 19.

PMID:
21129982
17.

Targeting the dynamic HSP90 complex in cancer.

Trepel J, Mollapour M, Giaccone G, Neckers L.

Nat Rev Cancer. 2010 Aug;10(8):537-49. doi: 10.1038/nrc2887. Review.

PMID:
20651736
18.

Hsp90 phosphorylation, Wee1 and the cell cycle.

Mollapour M, Tsutsumi S, Neckers L.

Cell Cycle. 2010 Jun 15;9(12):2310-6. Epub 2010 Jun 15.

19.

Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function.

Mollapour M, Tsutsumi S, Donnelly AC, Beebe K, Tokita MJ, Lee MJ, Lee S, Morra G, Bourboulia D, Scroggins BT, Colombo G, Blagg BS, Panaretou B, Stetler-Stevenson WG, Trepel JB, Piper PW, Prodromou C, Pearl LH, Neckers L.

Mol Cell. 2010 Feb 12;37(3):333-43. doi: 10.1016/j.molcel.2010.01.005.

20.

Phosphotyrosine confers client specificity to Hsp90.

Mayer MP.

Mol Cell. 2010 Feb 12;37(3):295-6. doi: 10.1016/j.molcel.2010.01.028.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk